Clinical aspects of the plurihormonal pituitary adenoma formation
https://doi.org/10.21886/2712-8156-2024-5-2-98-102
Abstract
Generally pituitary tumors have a benign growth, however, there are difficulties in diagnosis and treatment because of non-specific symptoms and the inability to predict the tumor growth. In clinical practice a hormonal activity of tumors has the significant role. To a greater extent, pituitary adenomas are prolactinomas, but the hypersecretion of prolactin could be combined with an excessive production of somatotropic hormone. In this case, the clinical picture of hyperprolactinemia is accompanied by acromegaly symptoms. The presented clinical case demonstrates the main reasons for the clinical appointment such as menstrual cycle disorders, prenatal preparation. A hyperprolactinemia has been detected, but as a treatment result, drug compensation was achieved and pregnancy occurred, then the woman gave birth without obstetric complications. Subsequently, other complaints arose, which expanded the diagnostic search and revealed the presence of a plurihormonal tumor.
About the Authors
I. A. Khripun
Rostov State Medical University
Russian Federation
Russian Federation
Irina A. Khripun - Dr. Sci. (Med.), Professor of the Department of Endocrinology (with the course of Pediatric Endocrinology).
Rostov-on-Don
S. V. Vorobyev
Rostov State Medical University
Russian Federation
Russian Federation
Sergey V. Vorobyev - Dr. Sci. (Med.), Professor of the Department of Endocrinology (with the course of Pediatric Endocrinology).
Rostov-on-Don
N. A. Kuzmenko
Rostov State Medical University
Russian Federation
Russian Federation
Natalia A. Kuzmenko - PhD, Associate Professor of the Department of Endocrinology (with the course of Pediatric Endocrinology).
Rostov-on-Don
E. S. Engibaryan
Rostov State Medical University
Russian Federation
Russian Federation
Elizaveta S. Engibaryan - Resident of the Department of Endocrinology (with a course in Pediatric Endocrinology).
Rostov-on-Don
V. O. Perevalova
Rostov State Medical University
Russian Federation
Russian Federation
Violetta O. Perevalova - Resident of the Department of Endocrinology (with a course in Pediatric Endocrinology).
Rostov-on-Don
References
1. Chin SO. Epidemiology of Functioning Pituitary Adenomas. Endocrinol Metab (Seoul). 2020;35(2):237-242. DOI: 10.3803/EnM.2020.35.2.237
2. Inder WJ, Jang C. Treatment of Prolactinoma. Medicina (Kaunas). 2022;58(8):1095. DOI: 10.3390/medicina58081095
3. Daly AF, Beckers A. The Epidemiology of Pituitary Adenomas. Endocrinol Metab Clin North Am. 2020;49(3):347-355. DOI: 10.1016/j.ecl.2020.04.002
4. Molitch ME. Diagnosis and Treatment of Pituitary Adenomas: A Review. JAMA. 2017;317(5):516-524. DOI: 10.1001/jama.2016.19699
5. Barry S, Korbonits M. Update on the Genetics of Pituitary Tumors. Endocrinol Metab Clin North Am. 2020;49(3):433-452. DOI: 10.1016/j.ecl.2020.05.005
6. Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, et al. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nat Rev Endocrinol. 2023;19(12):722-740. Erratum in: Nat Rev Endocrinol. 2023. PMID: 37670148.DOI: 10.1038/s41574-023-00886-5
7. Vilar L, Abucham J, Albuquerque JL, Araujo LA, Azevedo MF, Boguszewski CL, et al. Controversial issues in the management of hyperprolactinemia and prolactinomas - An overview by the Neuroendocrinology Department of the Brazilian Society of Endocrinology and Metabolism. Arch Endocrinol Metab. 2018;62(2):236-263. DOI: 10.20945/2359-3997000000032
8. Colao A, Di Sarno A, Guerra E, Pivonello R, Cappabianca P, Caranci F, et al. Predictors of remission of hyperprolactinaemia after long-term withdrawal of cabergoline therapy. Clin Endocrinol (Oxf). 2007;67(3):426-433. DOI: 10.1111/j.1365-2265.2007.02905.x
9. Dedov I.I., Melnichenko G.A., Dzeranova L.K., Andreeva E.N., Grineva E.N., Marova E.I., et al. Clinical guidelines ‘Hyperprolactinemia’ (draft). Obesity and metabolism. 2023;20(2):170-188. (In Russ.) DOI: 10.14341/omet13002
10. Cozzi R, Ambrosio MR, Attanasio R, Battista C, Bozzao A, Caputo M, et al. Position statement for clinical practice: prolactin-secreting tumors. Eur J Endocrinol. 2022;186(3):P1-P33. DOI: 10.1530/EJE-21-0977
11. Auriemma RS, Pirchio R, Pivonello C, Garifalos F, Colao A, Pivonello R. Approach to the Patient With Prolactinoma. J Clin Endocrinol Metab. 2023;108(9):2400-2423. DOI: 10.1210/clinem/dgad174
12. Ganz JC. Pituitary adenomas. Prog Brain Res. 2022;268(1):191-215. DOI: 10.1016/bs.pbr.2021.10.032
13. Ilovaiskaya I.A. Current views on the treatment of acromegaly with somatostatin analogues. Meditsinskiy sovet = Medical Council. 2017;(3):75-79. (In Russ.) DOI: 10.21518/2079-701X-2017-3-75-79
14. Dzeranova L.K., Aboishava L.A., Fedorova N.S., Vorotnikova S.Y., Pigarova E.A., Lapshina A.M. Difficulties in diagnosis of adenomas with mixed prolactin and growth hormone secretion: case presentation. Obesity and metabolism. 2020;17(3):233-240. (In Russ.) DOI: 10.14341/omet12669
Review
For citations:
Khripun I.A., Vorobyev S.V., Kuzmenko N.A., Engibaryan E.S., Perevalova V.O. Clinical aspects of the plurihormonal pituitary adenoma formation. South Russian Journal of Therapeutic Practice. 2024;5(2):98-102. (In Russ.) https://doi.org/10.21886/2712-8156-2024-5-2-98-102
Views:
321
Email this article 